Advertisement
Screener

ALPHA TEKNOVA, INC. (TKNO) Lease, Cost

2.8 / 5 stars · 68/120 Roast Me

ALPHA TEKNOVA, INC. Lease, Cost

ALPHA TEKNOVA, INC. (TKNO) reported Lease, Cost of $781.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:LeaseCost · last filed 2026-08-06

  • ALPHA TEKNOVA, INC. lease, cost for the quarter ending 2026-06-30 was $781.00K, a 2.01% decline year-over-year.
  • ALPHA TEKNOVA, INC. lease, cost for the quarter ending 2026-03-31 was $781.00K, a 2.01% decline year-over-year.
  • ALPHA TEKNOVA, INC. lease, cost for the quarter ending 2025-12-31 was $795.00K, a 6.80% decline year-over-year.
  • ALPHA TEKNOVA, INC. lease, cost for the quarter ending 2025-09-30 was $798.00K, a 6.56% decline year-over-year.
  • ALPHA TEKNOVA, INC. lease, cost for fiscal 2025 was $3.19M, a 6.65% decline from fiscal 2024.
  • ALPHA TEKNOVA, INC. lease, cost for fiscal 2024 was $3.42M, a 17.88% increase from fiscal 2023.
  • ALPHA TEKNOVA, INC. lease, cost for fiscal 2023 was $2.90M.
Period endLease, Cost 3 monthLease, Cost 6 monthLease, Cost 9 monthLease, Cost 12 month
2026-06-30$781.00K
10-Q · filed 2026-08-06
$1.56M
10-Q · filed 2026-08-06
$2.36M
derived: sum of 3 quarters · filed 2026-08-06
$3.15M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$781.00K
10-Q · filed 2026-05-07
$1.58M
derived: sum of 2 quarters · filed 2026-05-07
$2.37M
derived: sum of 3 quarters · filed 2026-05-07
$3.17M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$795.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$1.59M
derived: sum of 2 quarters · filed 2026-03-02
$2.39M
derived: sum of 3 quarters · filed 2026-08-06
$3.19M
10-K · filed 2026-03-02
2025-09-30$798.00K
10-Q · filed 2025-11-07
$1.59M
derived: sum of 2 quarters · filed 2026-08-06
$2.39M
10-Q · filed 2025-11-07
$3.25M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$797.00K
10-Q · filed 2026-08-06
$1.60M
10-Q · filed 2026-08-06
$2.45M
derived: sum of 3 quarters · filed 2026-08-06
$3.30M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$797.00K
10-Q · filed 2026-05-07
$1.65M
derived: sum of 2 quarters · filed 2026-05-07
$2.50M
derived: sum of 3 quarters · filed 2026-05-07
$3.36M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$853.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$1.71M
derived: sum of 2 quarters · filed 2026-03-02
$2.56M
derived: sum of 3 quarters · filed 2026-03-02
$3.42M
10-K · filed 2026-03-02
2024-09-30$854.00K
10-Q · filed 2025-11-07
$1.71M
derived: sum of 2 quarters · filed 2025-11-07
$2.56M
10-Q · filed 2025-11-07
$3.25M
derived: sum of 4 quarters · filed 2025-11-07
2024-06-30$854.00K
10-Q · filed 2025-08-08
$1.71M
10-Q · filed 2025-08-08
$2.40M
derived: sum of 3 quarters · filed 2025-08-08
$3.09M
derived: sum of 4 quarters · filed 2025-08-08
2024-03-31$854.00K
10-Q · filed 2025-05-09
$1.55M
derived: sum of 2 quarters · filed 2025-05-09
$2.24M
derived: sum of 3 quarters · filed 2025-05-09
$2.94M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31$692.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07
$1.39M
derived: sum of 2 quarters · filed 2025-03-07
$2.08M
derived: sum of 3 quarters · filed 2025-03-07
$2.90M
10-K · filed 2025-03-07
2023-09-30$694.00K
10-Q · filed 2024-11-08
$1.39M
derived: sum of 2 quarters · filed 2024-11-08
$2.21M
10-Q · filed 2024-11-08
2023-06-30$695.00K
10-Q · filed 2024-08-13
$1.51M
10-Q · filed 2024-08-13
2023-03-31$816.00K
10-Q · filed 2024-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92